Моксифлоксацин при тяжелой внебольничной пневмонии: первая возможность монотерапии?

1. Антибактериальная терапия пневмоний у взрослых: Учеб.-метод. пособие для врачей / Навашин С.М., Чучалин А.Г., Белоусов Ю.Б. и др. М.: РМ-Вести; 1998.

2. Падейская Е.Н., Яковлев В.П. Антимикробные препараты группы фторхинолонов в клинической практике. М.: Логата; 1998.

3. Яковлев В.П., Падейская Е.Н., Яковлев С.В. Ципрофлоксацин в клинической практике. М.: Информэлектро; 2000.

4. Baldwin D.R., Macfarlane J.T. Community-acquired pneumoniae. In: Armstrong D., Cohen J., eds. Infectious diseases. London: Mosby, Harcourt Publishers Ltd; 1999; chapt. 27: 27.1-27.10.

5. Bartlett J.G., Dowell S.F., Mandell L.A. et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2000; 31: 347-382.

6. Bartlett J.G. Management of respiratory tract infections. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001.

7. Blondeau J.M. Expanded activity and utility of the new fluoroquinolones: a review. Clin. Ther. 1999; 21 (1): 3-40.

8. The British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to the hospital. Br. J. Hosp. Med. 1993; 49: 346-350.

9. Donowitz G.R., Mandell G.L. Acute pneumoniae. In: Mandell G.L., Bennett J.E., Dolin R., eds. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. 717-743.

10. Drummond M., Finch R., Duprat-Lomon I. et al. Superior outcomes with moxifloxacin IV / P O monotherapy compared to IV /P O amoxicillin/clavulanate±clarithromycin in the treatment of community-acquired pneumonia. In: 41st Interscience conference on antimicrobial agents and chemotherapy, Chicago; 2001. Poster 864.

11. El-Solh A.A ., Sikka P., Ramadan F. et al. Etiology of severe pneumonia in the very elderly. Am. J. Respir. Crit. Care Med. 2001; 163: 645-651.

12. Ewig S., Schafer H., Torres A. Severity assessment of community-acquired pneumonia. Eur. Respir. J. 2000; 16: 1193-1201.

13. Felmingham D., Robbins M.J., Leakey A. et al. In vitro activity of moxifloxacin (BAY 12-8039), a novel 8-methoxyquinolone, compared with ofloxacin and other antibiotics. In: Adam D., Finch R., eds. Moxifloxacin in practice. Oxford: Maxim Medical Magdalene Centre; 1999: vol. 1: 27-37.

14. Finch R., Colins O., Kubin R. et al. Moxifloxacin IV /PO compared with amoxicillin/clavulanate IV /P O with or without clarithromycin in the treatment of community-acquired pneumonia. Clin. Microbiol. Infect. 2001; 7 (suppl.l): 167.

15. Fine M.J., Orloff J.J., Arisumi D. et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am. J. Med. 1990; 88: S1N-S8N.

16. Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify low-risk patient with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243-250.

17. Fine M.T., Smith M.A ., Carson C.A. et al. Prognosis and outcomes of patients with community-acquired pneumonia. J.A.M.A. 1996; 275: 134-142.

18. Grossman C., Choudhri S., Haverstock D. et al. Moxifloxacin (IV /PO ) for patients with severe community-acquired pneumonia. In: 39th Annual Meeting on the Infectious Disease Society of America. San Francisco; 2001. Poster 124.

19. Hakenbeck R. Pre-clinical microbiology — Streptococcus pneumoniae. In: Mandell L., ed. In: Proceedings of the First International moxifloxacin symposium. Berlin: Springer-Verlag; 1999. 21-26.

20. Leroy O., Santre C., Beuscart C. A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU. Intens. Care Med. 1995; 21: 24-31.

21. Luna C.M., Famiglietti A., Absi R. et al. Community-acquired pneumonia: etiology, epidemiology, and outcome in teaching hospital in Argentina. Chest 2000; 118: 1344-1354.

22. MacGowan A.P. Pharmacodynamics of moxifloxacin. In: Moxifloxacin in practice. Oxford: Maxim Medical Magdalen Centre; 1999; vol. 2: 5-13.

23. Mandell L.A., Marrie T.J., Grossman R.E. et al. Canadian guidelines for the initial management of community-acquired pneumonia. Clin. Infect. Dis. 2000; 31: 383-421.

24. Niederman M.S., Mandell L.A., Anzueto A. et al. American Thoracic Society: guidelines for the management of adults with community-acquired pneumoniae: diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. J. Resper. Crit. Care Med. 2001; 163: 1730-1754.

25. O’Donnell J.A., Gelone S.P. Fluoroquinolones. Infect. Dis. Clin. N. Am. 2000; 14: 489-513.

26. Read R.C., Pennington J.E. Respiratory tract infection. Oxford: Health Press Limited; 1998.

27. Read R.C. Clinical overview: moxifloxacin in community respiratory tract infections. In: Adam D., Finch R., eds. Moxifloxacin in practice. Oxford: Maxim Medical Magdalene Centre; 2000; vol. 3: 1-13.

28. Saravolatz L., Manzor O., Check C. et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. 2001; 47: 875-877.

29. Schentag J.J. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. J. Chemother. 2002; 14 (suppl.2): 13-21.

30. Tillotson G.S., Blondeau J.M. Today's community respiratiry tract infections: a challenge appropriate for moxifloxacin. In: Adam D., Finch R., eds. Moxifloxacin in practice. Oxford: Maxim Medical Magdalene Centre; 1999; vol. 1:1-11.